News

Wednesday, 2. July 2025 | Filed under Company News

Ebenbuild Secures Euro 2.3 Million EIC Grant to Scale Digital Twin Platform for Respiratory Health

— Funding supports market launch of platform for clinical and commercial applications

— Company targets Euro 15 billion in silico trials market and ICU decision support

Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. Read more…

Tuesday, 24. June 2025 | Filed under Company News

Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas

— Heat-triggered release mechanism unequivocally confirmed

— Favorable safety profile with good tolerability

— Signs of encouraging clinical activity in heavily pre-treated patients including meaningful progression-free survival (PFS)

— One participant with previously unresectable disease in DL2 underwent surgery, indicating no vital tumor cells in the target lesion

Munich, Germany – June 24, 2025 – Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Phase I clinical trial evaluating its lead compound THE001 (DPPG2-TSL-DOX) in combination with regional hyperthermia (RHT) for the treatment of soft tissue sarcomas (STS). Read more…

Tuesday, 17. June 2025 | Filed under Company News

Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients

Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected for residency in the Bayer Co.Lab incubator in Berlin.

The Bayer Co.Lab program supports cutting-edge biotech and life science innovators by providing access to fully equipped state-of-the-art lab and office infrastructure, global expertise, and Bayer’s broader life science ecosystem. Located at the headquarters of Bayer’s Pharmaceuticals Division, Bayer Co.Lab Berlin is a key hub in the company’s global incubator network, built to accelerate breakthrough technologies on their path to patients.

Read more…